Mahdi F, Shariat-Madar Z, Todd R F, Figueroa C D, Schmaier A H
Hematology and Oncology Division, Department of Internal Medicine and Pathology, University of Michigan, Ann Arbor, MI 48109-0640, USA.
Blood. 2001 Apr 15;97(8):2342-50. doi: 10.1182/blood.v97.8.2342.
The cellular localization of human cytokeratin 1 (CK1), urokinase plasminogen activator receptor (uPAR), and gC1qR, high-molecular-weight kininogen (HK)-binding proteins on endothelial cells, was determined. CK1 was found on the external membrane of nonpermeabilized endothelial cells by immunoperoxidase staining, immunofluorescence, and transmission electron microscopy using immunogold. Human umbilical vein endothelial cells (HUVECs) had 7.2 +/- 0.2 x 10(4) specific CK1 membrane sites/cell by (125)I-F(ab')(2) anti-CK1 antibody binding. Flow cytometry studies confirmed the presence of CK1, uPAR, and gC1qR on HUVECs. On laser scanning confocal microscopy and transmission electron microscopy, CK1 and uPAR, but not gC1qR, colocalized on the cell surface of HUVECs. The HUVEC surface distribution of these proteins was distinctly different from that for von Willebrand factor. In competitive inhibition experiments, anti-CK1, anti-uPAR, or anti-gC1qR blocked both biotin-HK binding and prekallikrein (PK) activation on HUVECs with an inhibitory concentration of 50% (IC(50)) of 300 to 350 nM, 50 to 60 nM, or 35 to 100 nM, respectively. Also, antibodies to uPAR and gC1qR each inhibited 86% of kallikrein-mediated, 2-chain urokinase plasminogen activation, whereas antibodies to CK1 only inhibited 24% of plasminogen activation. On HUVECs, CK1 and uPAR, but not gC1qR, colocalized to be a multiprotein receptor complex for HK binding, PK activation, and 2-chain urokinase plasminogen activation.
确定了人细胞角蛋白1(CK1)、尿激酶型纤溶酶原激活物受体(uPAR)和gC1qR、高分子量激肽原(HK)在内皮细胞上的结合蛋白的细胞定位。通过免疫过氧化物酶染色、免疫荧光以及使用免疫金的透射电子显微镜,在未通透的内皮细胞外膜上发现了CK1。人脐静脉内皮细胞(HUVECs)通过(125)I-F(ab')(2)抗CK1抗体结合,每个细胞有7.2±0.2×10(4)个特异性CK1膜位点。流式细胞术研究证实了HUVECs上存在CK1、uPAR和gC1qR。在激光扫描共聚焦显微镜和透射电子显微镜下,CK1和uPAR,但不是gC1qR,共定位于HUVECs的细胞表面。这些蛋白在HUVEC表面的分布与血管性血友病因子明显不同。在竞争性抑制实验中,抗CK1、抗uPAR或抗gC1qR均可阻断HUVECs上生物素-HK的结合和前激肽释放酶(PK)的激活,其50%抑制浓度(IC(50))分别为300至350 nM、50至60 nM或35至100 nM。此外,抗uPAR和抗gC1qR抗体分别抑制86%的激肽释放酶介导的双链尿激酶型纤溶酶原激活,而抗CK1抗体仅抑制24%的纤溶酶原激活。在HUVECs上,CK1和uPAR,但不是gC1qR,共定位于一个用于HK结合、PK激活和双链尿激酶型纤溶酶原激活的多蛋白受体复合物。